|
|
||||||||
Ann Thorac Surg 1995;60:292-299
© 1995 The Society of Thoracic Surgeons
Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina
Background. The active form of thyroid hormone, T3, may be an important determinant of left ventricular (LV) function after hypothermic cardioplegic arrest and rewarming, particularly in patients with preexisting LV dysfunction. Thus, the present project tested the hypothesis that T3 pretreatment will improve myocyte contractile performance after hypothermic cardioplegic arrest and rewarming in the setting of chronic LV dysfunction.
Methods. Control LV porcine myocytes (n = 160) and cardiomyopathic LV (rapid pacing for 3 weeks at 240 beats/min) myocytes (n = 100) were treated with or without 80 pmol/L T3. Myocytes then were maintained in normothermic conditions (2 hours at 37°C in media) or exposed to hypothermic cardioplegic arrest ([K+], 24 mmol/L; 2 hours at 4°C) with subsequent rewarming.
Results. After cardioplegic arrest and rewarming, T3 pretreatment increased myocyte velocity of shortening by 41% in control myocytes and by 35% in cardiomyopathic myocytes when compared to untreated myocytes. Furthermore, T3 pretreatment followed by ß-adrenergic receptor stimulation with isoproterenol (25 nmol/L) improved myocyte velocity of shortening by 24% in control myocytes and 90% in cardiomyopathic myocytes after hypothermic cardioplegic arrest and rewarming, as compared with untreated myocytes.
Conclusions. In summary, this study provides evidence to suggest that preemptive treatment with T3 may improve LV pump function and ß-adrenergic responsiveness after hypothermic cardioplegic arrest and rewarming in patients with underlying LV dysfunction.
Related Article
Ann. Thorac. Surg. 1995 60: 299.
This article has been cited by other articles:
![]() |
O. Lund and M. Bland Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement J. Thorac. Cardiovasc. Surg., July 1, 2006; 132(1): 20 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. U. Syed, A. F El Watidy, N B. Akhlaque, A. Wahba, R. M El Oakley, K. Imran, E. A Al Bukhari, and M. R Al Fagih Coronary Bypass Surgery in Patients on Thyroxin Replacement Therapy Asian Cardiovasc Thorac Ann, June 1, 2002; 10(2): 107 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Spinale Cellular and molecular therapeutic targets for treatment of contractile dysfunction after cardioplegic arrest Ann. Thorac. Surg., November 1, 1999; 68(5): 1934 - 1941. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Mullis-Jansson, M. Argenziano, S. Corwin, S. Homma, A. D. Weinberg, M. Williams, E. A. Rose, and C. R. Smith A RANDOMIZED DOUBLE-BLIND STUDY OF THE EFFECT OF TRIIODOTHYRONINE ON CARDIAC FUNCTION AND MORBIDITY AFTER CORONARY BYPASS SURGERY J. Thorac. Cardiovasc. Surg., June 1, 1999; 117(6): 1128 - 1135. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Murai, Y. Katayama, T. Yamada, T. Imazeki, Y. Irie, H. Kiyama, Y. Sato, I. Hata, H. Yoshida, and M. Mukouyama Thyroid Hormone and Myocardial Metabolism After Heart Surgery in Dogs Asian Cardiovasc Thorac Ann, March 1, 1999; 7(1): 13 - 17. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Cimochowski, M. D. Harostock, and P. J. Foldes MINIMAL OPERATIVE MORTALITY IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS WITH SIGNIFICANT LEFT VENTRICULAR DYSFUNCTION BY MAXIMIZATION OF METABOLIC AND MECHANICAL SUPPORT J. Thorac. Cardiovasc. Surg., April 1, 1997; 113(4): 655 - 666. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |